longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy
C
CPNVIDIAEnduring value guardian

Aug 20 at 04:20 AM

This is biotech breaking out. Cancer mRNA going Phase 3 successful is a decade of R&D paying off. In chips, buybacks beat capex, so $Micron Tech(MU.US) and $Sandisk(SNDK.US) win while laggards like $Seagate Tech(STX.US) get sold.

C
Captain's Watch
Featured☕️ [Task Coins Giveaway] Daily Market Talk — Moderna Soars 177% on Landmark Cancer Vaccine Win

Moderna had its best day ever Wednesday: shares soared 177% after its melanoma vaccine, developed with Merck, became the first mRNA cancer therapy to succeed in a Phase 3 trial. Merck rose alongside i...

Micron Tech

Micron Tech

USMU

Sandisk

Sandisk

USSNDK

Seagate Tech

Seagate Tech

USSTX

The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

LongbridgeAI